Apex Biotechnology Corp (1733) — Cash Flow-to-Debt Ratio
Apex Biotechnology Corp (1733) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of NT$5.19 Million could theoretically repay 0% of its total liabilities (NT$494.69 Million) in one year. See Apex Biotechnology Corp free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Apex Biotechnology Corp Cash Flow-to-Debt Ratio (2002–2024)
Historical debt coverage capacity for Apex Biotechnology Corp across 23 annual periods. Also explore Apex Biotechnology Corp (1733) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Apex Biotechnology Corp (2002–2024)
Year-by-year debt coverage analysis for Apex Biotechnology Corp. For market capitalisation and broader financial context, see Apex Biotechnology Corp stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.55x | NT$328.67 Million | NT$595.70 Million | ▲ +19.8% |
| 2023 | 0.46x | NT$230.39 Million | NT$500.07 Million | ▲ +1106.2% |
| 2022 | 0.04x | NT$26.62 Million | NT$696.81 Million | ▼ -80.5% |
| 2021 | 0.20x | NT$179.87 Million | NT$916.91 Million | ▼ -29.7% |
| 2020 | 0.28x | NT$280.60 Million | NT$1.01 Billion | ▼ -31.4% |
| 2019 | 0.41x | NT$462.52 Million | NT$1.14 Billion | ▲ +442.7% |
| 2018 | 0.07x | NT$67.57 Million | NT$901.70 Million | ▲ +9.5% |
| 2017 | 0.07x | NT$70.83 Million | NT$1.03 Billion | ▼ -82.4% |
| 2016 | 0.39x | NT$298.06 Million | NT$768.49 Million | ▼ -37.2% |
| 2015 | 0.62x | NT$472.15 Million | NT$764.69 Million | ▲ +79.6% |
| 2014 | 0.34x | NT$267.60 Million | NT$778.52 Million | ▼ -43.0% |
| 2013 | 0.60x | NT$484.77 Million | NT$803.47 Million | ▼ -13.0% |
| 2012 | 0.69x | NT$509.67 Million | NT$735.18 Million | ▼ -1.4% |
| 2011 | 0.70x | NT$273.45 Million | NT$388.76 Million | ▼ -51.6% |
| 2010 | 1.45x | NT$465.59 Million | NT$320.60 Million | ▲ +12.6% |
| 2009 | 1.29x | NT$391.29 Million | NT$303.31 Million | ▼ -4.9% |
| 2008 | 1.36x | NT$299.96 Million | NT$221.21 Million | ▼ -23.8% |
| 2007 | 1.78x | NT$364.62 Million | NT$204.80 Million | ▼ -4.2% |
| 2006 | 1.86x | NT$363.71 Million | NT$195.73 Million | ▲ +95.7% |
| 2005 | 0.95x | NT$212.14 Million | NT$223.36 Million | ▼ -44.1% |
| 2004 | 1.70x | NT$218.54 Million | NT$128.64 Million | ▼ -31.4% |
| 2003 | 2.48x | NT$302.25 Million | NT$122.00 Million | ▲ +178.0% |
| 2002 | 0.89x | NT$79.49 Million | NT$89.21 Million | — |